Introduction {#onco12682-sec-0006}
============

Advances in genomic technologies have led to identification of genes commonly perturbed in cancer. Genomic testing has been quickly adopted and widely implemented in cancer care to leverage treatment decision‐making and improve treatment outcomes \[[1](#onco12682-bib-0001){ref-type="ref"}\], \[[2](#onco12682-bib-0002){ref-type="ref"}\]. Although technologies such as next‐generation sequencing (NGS) are increasingly accepted in nonhematologic malignancies, the genomic landscape of Hodgkin lymphoma (HL) remains to be described.

In 2016, an estimated 8,500 new cases of HL were diagnosed in the U.S. \[[3](#onco12682-bib-0003){ref-type="ref"}\]. Although rates of survival have improved over the years, approximately 10% of early‐stage HL patients and 20%--30% of advanced‐stage patients become refractory after initial therapy \[[4](#onco12682-bib-0004){ref-type="ref"}\]. Furthermore, late treatment‐related sequelae may lead to significant morbidity and mortality. Therapeutic options for patients with relapsed or refractory disease include salvage chemotherapy, followed by high‐dose chemotherapy and autologous stem cell transplantation (ASCT). For patients refractory to primary therapy, even with aggressive approaches such as ASCT, overall survival rates do not exceed 30% \[[5](#onco12682-bib-0005){ref-type="ref"}\]. Patients who relapse after ASCT may be candidates for allogeneic stem cell transplantation (alloSCT), which yields a median overall survival of 29 months with an approximate 20% treatment‐related mortality \[[6](#onco12682-bib-0006){ref-type="ref"}\]. Patients relapsing after ASCT and/or alloSCT have only limited treatment options, which include brentuximab vedotin, lenalidomide, bendamustine, or programmed cell death protein 1 (PD‐1) antibodies, with median survival usually not exceeding 24 months \[[4](#onco12682-bib-0004){ref-type="ref"}\], \[[7](#onco12682-bib-0007){ref-type="ref"}\]. Therefore, a pressing need exists to better understand the underlying disease biology, which may lead to improvement in treatment outcomes. Investigation of the genomic landscape of HL has been difficult because of the low tumor content in these inflammatory cell‐ and stroma‐rich tissue samples. Therefore, we performed a study using comprehensive genomic profiling (CGP) with a targeted NGS panel to test for genomic aberrations in archival tumor samples from patients with HL in order to identify potentially actionable molecular targets.

Materials and Methods {#onco12682-sec-0007}
=====================

Patients and Tumor Samples {#onco12682-sec-0008}
--------------------------

Formalin‐fixed paraffin‐embedded (FFPE) archival tumor samples, procured during routine clinical procedures for 63 HL patients, were reviewed and evaluated.

Comprehensive Genomic Profiling {#onco12682-sec-0009}
-------------------------------

A single hematoxylin and eosin‐stained slide was examined in order to confirm the presence of tumor. CGP was performed from FFPE tissue using the Clinical Laboratory Improvement Amendments‐certified, College of American Pathologists‐accredited, New York State‐approved FoundationOne (DNA‐seq) \[[8](#onco12682-bib-0008){ref-type="ref"}\] or FoundationOne Heme (DNA/RNA‐seq) \[[9](#onco12682-bib-0009){ref-type="ref"}\] assay. A minimum of 50 ng of DNA and 300 ng of RNA were extracted, RNA was converted to complementary DNA, and DNA was sonicated with subsequent adaptor ligation and hybridization capture, as described previously \[[8](#onco12682-bib-0008){ref-type="ref"}\], \[[9](#onco12682-bib-0009){ref-type="ref"}\]. DNA‐based captured libraries (up to 405 cancer‐related genes plus select introns from 31 genes) were sequenced to a median unique exon coverage depth of 500× using Illumina sequencing, and, following removal of duplicate reads, were analyzed for base substitutions, insertions, deletions, copy number alterations (focal gene amplifications and homozygous deletions), and select gene fusions. RNA‐based captured libraries (265 genes) achieved ≥3M on‐target unique pairs and were analyzed only for the presence of rearrangements. Total mutation burden (TMB) was defined as the number of somatic coding base substitutions and indel alterations minus known driver alterations per megabase (Mb) of genome examined, adjusted for the tumor content to allow for cross‐study comparisons. A TMB of ≥20 mutations/Mb was considered high; 6--19 mutations/Mb intermediate; and ≤5 mutations/Mb low.

Plasma Collection and Cell‐Free DNA Testing for the XPO1^E571^ Mutation {#onco12682-sec-0010}
-----------------------------------------------------------------------

Whole blood was collected in ethylenediaminetetraacetic acid‐containing tubes and centrifuged and spun twice within 2 hours to yield plasma. We extracted cell‐free DNA (cfDNA) from plasma samples collected from 13 relapsed/refractory Hodgkin lymphoma patients before initiation of systemic therapy using the QIAamp Circulating Nucleic Acid Kit (Qiagen, Valencia, CA) according to the manufacturer\'s instructions. In order to identify common *XPO1* mutations in plasma cfDNA, we designed droplet digital polymerase chain reaction (ddPCR) probes against the E571K and E571V mutations. Sixteen nanograms of unamplified cfDNA was tested using ddPCR for the presence of the *XPO1* E571K or *XPO1* E571V mutation to distinguish the wild‐type allele from the mutant using the QX200 Droplet Digital PCR platform (Bio‐Rad, Pleasanton, CA) according to the manufacturer\'s standard protocol. The lower limit of detection was approximately \<0.1% mutant allele frequency (MAF) per single well.

Results {#onco12682-sec-0011}
=======

Comprehensive Genomic Profiling of Archival Tumor Tissue {#onco12682-sec-0012}
--------------------------------------------------------

Molecular profiling was successfully performed in 49 (78%) of the 63 classical Hodgkin lymphoma FFPE specimens (Fig. [1](#onco12682-fig-0001){ref-type="fig"}; Table [1](#onco12682-tbl-0001){ref-type="table"}). Of these 49 specimens, 9 (18%) had no alterations, and in 40 specimens, a total of 44 genes with 95 alterations, including nonsynonymous mutations, splice site changes, rearrangements, or copy number alterations, were identified. Detailed patient characteristics were available for 18 patients treated at MD Anderson Cancer Center (Table [2](#onco12682-tbl-0002){ref-type="table"}).

![Enrollment of Hodgkin lymphoma patients whose archival tumor tissue was submitted for comprehensive genomic profiling.](onco12682-fig-0001){#onco12682-fig-0001}

###### Comprehensive genomic profiling of archival tumor tissue in Hodgkin lymphoma patients

![](onco12682-tbl-0001){#nlm-graphic-5}

Abbreviations: F1, FoundationOne (DNA‐seq); F1H, FoundationOne Heme (DNA/RNA); NA, not available; ND, not done; TMB, total mutation burden; X, a test was performed for this patient (DNA test, or RNA test).

###### Patients' characteristics for 18 patients treated at MD Anderson Cancer Center

![](onco12682-tbl-0002){#nlm-graphic-7}

Abbreviations: EBER, EBV‐encoded RNA; EBV, Epstein‐Barr virus; HL, Hodgkin lymphoma; NOS, not otherwise specified.

The most commonly mutated gene was *TP53* (tumor protein p53) with 13 mutations in 11 patients (22%; Table [1](#onco12682-tbl-0001){ref-type="table"}; Fig. [2](#onco12682-fig-0002){ref-type="fig"}). The next most commonly mutated gene was *B2M* (beta‐2 microglobulin) with 12 mutations in 11 patients (22%; Table [1](#onco12682-tbl-0001){ref-type="table"}; Fig. [2](#onco12682-fig-0002){ref-type="fig"}). For 82% (9/11) of patients with *B2M* alterations (with patient 2 demonstrating two *B2M* mutations), mutations occurred at the M1 position (M1I, *n* = 2; M1K, *n* = 5; M1R, *n* = 1; M1T, *n* = 1; M1V, *n* = 1; Table [1](#onco12682-tbl-0001){ref-type="table"}). The next most frequently mutated gene was *XPO1* (exportin 1; *CRM1*), for which nine (18%) cases harbored an E571 mutation (E571K: *n* = 8, E571V: *n* = 1; Table [1](#onco12682-tbl-0001){ref-type="table"}; Fig. [2](#onco12682-fig-0002){ref-type="fig"}). These mutations were not mutually exclusive of *TP53* or *B2M* aberrations. For two of these nine patients, an *XPO1* mutation (E571K: *n* = 1, E571V: *n* = 1) was the only panel gene demonstrating an aberration, whereas the remaining seven patients demonstrated 1 through 20 additional mutations. The next most frequently mutated genes include *TNFAIP3* (tumor necrosis factor, alpha‐induced protein 3) and *SOCS1* (suppressor of cytokine signaling 1). Eight aberrations in *TNFAIP3* were identified in seven patients (14%; Table [1](#onco12682-tbl-0001){ref-type="table"}; Fig. [2](#onco12682-fig-0002){ref-type="fig"}). Notably, two events were nonsense mutations and the remaining six were frameshift events, with two of these occurring in patient 23. Five events were additionally identified in *SOCS1* across five patients (10%; Table [1](#onco12682-tbl-0001){ref-type="table"}; Fig. [2](#onco12682-fig-0002){ref-type="fig"}). Three missense mutations, each occurring in three separate patients, were identified, along with rearrangements in patients 7 and 39. In both patients 7 and 39, an *IGH‐SOCS1* rearrangement was identified, with a breakpoint occurring in exon two, the only coding exon, of *SOCS1*. In three of the five patients demonstrating *SOCS1* aberrations, the identified *SOCS1* mutation was the only event identified from CGP (Fig. [2](#onco12682-fig-0002){ref-type="fig"}). Programmed death‐ligand 1 (PD‐L1) amplification was also uncommon with only one case (patient 2) whose tumor harbored amplification of *CD274*.

![Molecular alterations in archival tumor samples from 40 Hodgkin lymphoma patients. The nine patients for whom comprehensive genomic profiling did not identify alterations are not shown. Split squares are shown if two events were identified in the same gene (e.g., *B2M* and *TP53* for patient 2).](onco12682-fig-0002){#onco12682-fig-0002}

Of the 34 patients for whom TMB was assessed, 5 (15%) had high TMB, 18 (53%) had intermediate TMB, and 11 (32%) had low TMB (Fig. [3](#onco12682-fig-0003){ref-type="fig"}). Only two patients, both with intermediate TMB, received anti‐PD‐1 antibodies, and both patients responded to treatment.

![Total mutation burden for 34 Hodgkin lymphoma patients. High mutation burden is depicted in red, intermediate in orange, and low in blue. Two patients (yellow stars) received anti‐programmed cell death protein 1 antibodies and responded to treatment. Abbreviation: Mb, megabase.](onco12682-fig-0003){#onco12682-fig-0003}

ddPCR of Plasma cfDNA for *XPO1* E571 Mutations {#onco12682-sec-0013}
-----------------------------------------------

To confirm if recurrent *XPO1* E571 mutations are measureable in blood plasma and have the potential to act as a biomarker, ddPCR of cfDNA was performed. Of the 13 patients whose tumor samples were subjected to ddPCR analysis, 3 had *XPO1* E571K mutations (MAFs of 6.10%, 2.07%, and 6.10%, respectively) and 1 had the *XPO1* E571V mutation (MAF of 2.70%). Among these four patients' cases, CGP of the tumor tissue had not been performed in one case, *XPO1* mutation was not detected by profiling in one case, no results were obtained by profiling for one case, and the *XPO1* E571V mutation was confirmed in the tumor in one case (Table [3](#onco12682-tbl-0003){ref-type="table"}). Among the remaining nine cases in which ddPCR did not detect *XPO1* E571K or E571V mutations in cfDNA, CGP did not produce results in one case, demonstrated no *XPO1* mutation in one case, and was not performed for seven cases (Table [3](#onco12682-tbl-0003){ref-type="table"}). All three patients whose cfDNA had *XPO1* E571K mutations had longitudinal collection of plasma during systemic therapy, and changes in *XPO1* E571K MAFs corresponded to changes in tumor size on conventional radiographic imaging with positron emission tomography‐computed tomography (Fig. [4](#onco12682-fig-0004){ref-type="fig"}).

###### *XPO1* mutations in plasma cfDNA

![](onco12682-tbl-0003){#nlm-graphic-17}

Three patients that were profiled by CGP also had cfDNA analysis (patients 7, 40, 41). Patients with letter identifiers were not profiled by CGP.

Abbreviations: cfDNA, cell‐free DNA; CGP, comprehensive genomic profiling; ddPCR, droplet digital polymerase chain reaction; MAF, mutant allele frequency.

![Dynamic changes in *XPO1* E571K MAF. Changes in *XPO1* E571K MAF in plasma cell‐free DNA are shown as blue graph lines. Changes in tumor size, represented by the sum of perpendicular diameters of target tumor lesions evaluated by Cheson criteria (orange bars), in two Hodgkin lymphoma patients treated with mTOR and HDAC inhibitors **(A and B)** and one patient treated with mTOR and HDAC inhibitors followed by an anti‐CTLA4 antibody plus lenalidomide **(C)**, are also shown. Abbreviations: CTLA4, cytotoxic T‐lymphocyte associated protein 4; HDAC, histone deacetylase; MAF, mutant allele frequency; mTOR, mammalian target of rapamycin.](onco12682-fig-0004){#onco12682-fig-0004}

Discussion {#onco12682-sec-0014}
==========

Our study demonstrates that CGP using targeted NGS of FFPE archival tumor samples from Hodgkin lymphoma patients is feasible. We observed a spectrum of alterations distributed across 44 cancer‐related genes; the most commonly mutated genes were *TP53* (22% of patients), *B2M* (22% of patients), and *XPO1* (18% of patients). We also detected *XPO1* E571K or E571V mutations in 31% of the assayed plasma cfDNA samples. To our knowledge, our study is the first to report analysis of the genomic landscape of Hodgkin lymphoma using archival tumor samples.

Large‐scale genomic profiling has been challenging because of the nature of the disease, as Hodgkin and Reed‐Sternberg (HRS) cells are relatively sparse in the stroma‐rich environment \[[10](#onco12682-bib-0010){ref-type="ref"}\]. To address this problem, researchers have performed flow sorting of these cells to prepare samples for whole exome sequencing. Reichel et al. \[[10](#onco12682-bib-0010){ref-type="ref"}\] used this approach for 10 fresh tumor samples and detected *B2M* alterations in 80% of cases. Other alterations including *XPO1* mutations have also been reported; however, the need for fresh tumor tissue limits the clinical utility of this approach. Notably, we did not perform microdissection of HRS cells in this study.

Others have also assessed the genomic profiles of tumor biopsies and plasma‐derived cfDNA. Camus et al. \[[11](#onco12682-bib-0011){ref-type="ref"}\] reported *XPO1* E571K mutations in 24% of tumor biopsies and in approximately 50% of plasma cfDNA samples from Hodgkin lymphoma patients; however, the investigators used ddPCR, which was not designed to detect alterations in cancer‐related genes other than *XPO1*. We improve upon these studies by performing genomic profiling of more readily available archival tumor specimens in order to evaluate the genomic landscape of Hodgkin lymphoma.

In our study, *TP53* mutations were among the most frequent molecular abnormalities, occurring in 22% of patients. Previous studies have reported lower frequency of *TP53* mutations, which occurred in approximately 9%--11% of Hodgkin lymphoma patients \[[12](#onco12682-bib-0012){ref-type="ref"}\], \[[13](#onco12682-bib-0013){ref-type="ref"}\]. However, previous studies suggested that *TP53* mutation frequency might be associated with enrichment for HRS cells \[[14](#onco12682-bib-0014){ref-type="ref"}\], \[[15](#onco12682-bib-0015){ref-type="ref"}\]. Arguably, samples meeting quality standards for the CGP could have been plausibly enriched for HRS cells. Unfortunately, a small sample size precluded analysis of prognostic significance. Molecular alterations in *B2M* were also among the most frequently detected molecular abnormalities. *B2M* inactivating mutations result in a loss of expression of the major histocompatibility complex class I complex, which is involved in antigen presentation. Decreased expression of *B2M* has also been reported to be associated with worse prognosis in non‐Hodgkin lymphoma patients \[[16](#onco12682-bib-0016){ref-type="ref"}\]. Notably, inactivating *B2M* mutations have been observed in Hodgkin lymphoma patients, and lack of *B2M* expression has been associated with a favorable prognosis \[[10](#onco12682-bib-0010){ref-type="ref"}\]. With respect to therapeutic insights, one recent study suggested that truncating *B2M* mutations may be associated with acquired resistance to PD‐1 blockade in metastatic melanoma \[[10](#onco12682-bib-0010){ref-type="ref"}\]. These studies, along with our findings, demonstrate the benefits of genomic profiling to improve our understanding of the genomic landscape of Hodgkin lymphoma tumors, as well as to improve therapeutic selection.

Other frequent recurrent alterations in the present study were *XPO1* E571 mutations, which were detected in 18% of archival tumor samples and 31% of plasma cfDNA samples. Small numbers precluded assessment of concordance between plasma cfDNA and tumor tissue testing. XPO1 regulates the nuclear export and localization of proteins involved in cell proliferation and the cell cycle. Increased expression of *XPO1* in cancer patients has been shown to be associated with worse survival and increased metastasis \[[17](#onco12682-bib-0017){ref-type="ref"}\], and mutations in this gene have been reported in B‐cell lymphoma \[[18](#onco12682-bib-0018){ref-type="ref"}\]. A recent study using ddPCR reported recurrent *XPO1* E571K mutations in 24% of tumor biopsies and about 50% of plasma cfDNA samples from Hodgkin lymphoma patients \[[11](#onco12682-bib-0011){ref-type="ref"}\]. Currently, XPO1 inhibitors such as selinexor are being evaluated in solid tumors and hematologic malignancies in clinical trials; however, the possible relationship between *XPO1* mutations and sensitivity or resistance to XPO1 inhibition remains unknown because preclinical data on B‐cell lymphoma and osteosarcoma cell lines demonstrated efficacy independent of *XPO1* mutation status \[[18](#onco12682-bib-0018){ref-type="ref"}\].

Other potentially targetable molecular alterations identified in our study include loss of *TSC2* (tuberous sclerosis 2), for which mammalian target of rapamycin inhibitors may be effective \[[19](#onco12682-bib-0019){ref-type="ref"}\]; and a *BRCA1* mutation, which suggests treatment with DNA‐damaging platinum agents or poly(ADP‐ribose) polymerase inhibitors \[[20](#onco12682-bib-0020){ref-type="ref"}\], \[[21](#onco12682-bib-0021){ref-type="ref"}\]. However, the one *BRCA1* mutation we identified may be a germline event given the event\'s allelic frequency of 46% and the patient\'s family history of breast cancer. Previous studies have reported that germline *BRCA1* mutations are infrequent in Hodgkin lymphoma \[[22](#onco12682-bib-0022){ref-type="ref"}\].

We also identified recurrent events in *TNFAIP3* (14% of patients) and *SOCS1* (10% of patients). *TNFAIP3* is involved in the regulation of apoptosis and nuclear factor κB signaling, and the nonsense and frameshift mutations we identified are predicted to be inactivating due to the predicted translation of a truncated protein. Deletions, mutations, and decreased protein expression of *TNFAIP3* have been reported in approximately 24%--44% of Hodgkin lymphoma patients and in 10%--38% of non‐Hodgkin lymphoma patients \[[23](#onco12682-bib-0023){ref-type="ref"}\], \[[24](#onco12682-bib-0024){ref-type="ref"}\]. With respect to *SOCS1*, S116N has been reported in diffuse large B‐cell lymphoma \[[25](#onco12682-bib-0025){ref-type="ref"}\], and A17T has been reported in B‐cell lymphoma \[[26](#onco12682-bib-0026){ref-type="ref"}\]. A17T is outside of the gene\'s functional domains, but S116N is in the gene\'s conserved Src Homology 2 domain and thus may affect protein interactions if expressed. Mutations in *SOCS1*, which has roles in apoptosis, and in cell survival and growth through JAK/STAT signaling, have also been reported in Reed‐Sternberg cells and Hodgkin cell lines as inactivating mutations \[[27](#onco12682-bib-0027){ref-type="ref"}\]. The *SOCS1* rearrangement we identified in patients 7 and 39 is also predicted to be inactivating as it disrupts the only coding exon of *SOCS1*. This event is similar to a t(14;16)(q32;p13.1) event that was previously described in a Hodgkin lymphoma patient \[[28](#onco12682-bib-0028){ref-type="ref"}\].

High TMB was recently found to be predictive of favorable response to PD‐1‐ and PD‐L1‐targeted therapies in lung cancer \[[29](#onco12682-bib-0029){ref-type="ref"}\]. In our study, 15% patients with TMB data had high TMB. However, only two patients with known TMB received PD‐1 antibodies, and both responded despite having intermediate TMB. Thus, the relationship between TMB and response to immune checkpoint inhibitors remains to be clarified.

We further show that ddPCR is a highly sensitive approach that can detect *XPO1* E571 mutations in plasma cfDNA samples from Hodgkin lymphoma patients. Using ddPCR, we detected *XPO1* E571 mutations in 31% of cases, and we were able to confirm the mutation in archival tumor samples in three of the four cases for which tumor tissue was available. In addition, dynamic tracking of *XPO1* MAF corresponded with changes observed during routine radiographic imaging. Previously, Camus et al. \[[11](#onco12682-bib-0011){ref-type="ref"}\] reported that ddPCR detected *XPO1* E571K mutations in about 50% of plasma cfDNA samples; however, in nearly half those cases, the *XPO1* mutation was not confirmed in the tumor tissue. Also, patients with detectable *XPO1* mutation in plasma cfDNA at the end of therapy had a trend toward shorter progression‐free survival.

Our study has several potential limitations. First, the sample size was relatively small, and second, CGP encompassed up to 405 selected cancer‐related genes such that novel events may be missed. In addition, our method did not include testing of normal DNA to reliably exclude possible germline alterations. Third, our method did not include sorting the HRS cells. Therefore, it is unclear if all reported variants are truly from HRS cells. Fourth, although we were able to obtain TMB data for a considerable number of patients, only a few patients received checkpoint inhibitors; thus, the value of TMB in predicting immunotherapy response remains unknown. In addition, whether any of the recurrent molecular alterations we identified may be used for therapeutic decision‐making remains unclear. Furthermore, profiling of degraded FFPE DNA lends itself to the possibility of false negatives. For example, previous studies have reported a recurrence of *PD‐L1/CD274* and *PD‐L2/PDCD1LG2* amplification in newly diagnosed HL cases \[[30](#onco12682-bib-0030){ref-type="ref"}\] and nodular sclerosis HL \[[31](#onco12682-bib-0031){ref-type="ref"}\]. However, only one patient profiled here (33 of 49 were tested for *PD‐L1/CD274* and *PD‐L2/PDCD1LG2* amplification as these genes were not initially included in the panel) demonstrated PD‐L1 amplification such that this caveat must be considered during data interpretation. Finally, the roles of *B2M* and *XPO1* mutations as possible biomarkers of response to XPO1 inhibitors or immune checkpoint inhibitors, respectively, remain to be evaluated in preclinical and prospective clinical studies.

Conclusion {#onco12682-sec-0015}
==========

Overall, we demonstrate the feasibility of performing CGP on archival tumor specimens from Hodgkin lymphoma patients. In addition to improving our understanding of the genomic landscape of Hodgkin lymphoma, we identified recurrent alterations in the *TP53*, *B2M*, *XPO1*, and *TNFAIP3* genes. Fifteen percent of patients demonstrated high TMB, which in other cancers was found to be associated with activity of immune checkpoint inhibitors. We further show that *XPO1* mutations may be detected in patient cfDNA, and that changes in the MAF of cfDNA *XPO1* mutations correlate with changes in tumor size. As a result, these findings provide potential strategies for therapeutic selection and molecular monitoring of patients. Continued genomic analysis of Hodgkin lymphoma patients thus creates a foundation for improving patient care.
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